Baxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow BAX
Baxter International Inc. 10-K filed Feb 12, 2026
Red flags
-
Impairment
Baxter International Inc. recorded a goodwill impairment of $485.0 million in fiscal 2025
What changed
Item 1, Business, against the 10-K filed Feb 21, 2025: 2 added · 4 removed · 39 modified; 1 with only figures updated
-
Modified · Company Overview
Baxter International Inc., through
itsour subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products,; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries. As of December 31,20242025, after giving effect to therecentsale of our Kidney Care business (as discussed below), we manufactured products in over 20 countries and sold them in over 100 countries.
44 more changes in this Item, word by word, in Powerpack.
Powerpack